Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients survival and quality of life

Anti-Cancer Drugs

Volumn 19, Issue 6, 2008, Pages 645-653

  Azim Jr , Hatem A ^a,c   Mok, Tony ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

Bisphosphonates; Estramustine; Hormone refractory prostate cancer; Targeted agents

Indexed keywords

ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CAPECITABINE; CLODRONIC ACID; CYTOTOXIC AGENT; DOCETAXEL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; ETOPOSIDE; GEFITINIB; IBANDRONIC ACID; IXABEPILONE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; PERTUZUMAB; PLATINUM DERIVATIVE; PREDNISONE; PROTEIN BCL 2; UNINDEXED DRUG; VASCULOTROPIN; VINBLASTINE; VITAMIN D RECEPTOR; ZOLEDRONIC ACID; CALCITRIOL RECEPTOR; CISPLATIN; PYRROLIDINE DERIVATIVE; TAXOID;

ADVANCED CANCER; ANGIOGENESIS; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; HEADACHE; HUMAN; NEUROTOXICITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RHINITIS; DRUG ANTAGONISM; MALE; MORTALITY; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT;

CISPLATIN; DIPHOSPHONATES; HUMANS; MALE; MITOXANTRONE; PACLITAXEL; PROSTATIC NEOPLASMS; PYRROLIDINES; QUALITY OF LIFE; RECEPTORS, CALCITRIOL; TAXOIDS;

EID: 53749104891     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282ff0f48     Document Type: Review

References (92)

1. American Cancer Society: Prostate cancer statistics. http:// www.cancer.org/docroot/home/index.asp
2. National Cancer Institute of Canada: Canadian Cancer Statistics, 2003. Toronto, Canada, National Cancer Institute of Canada, 2003.
3. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, Mcleod DG, Wilding G, et al.Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med1998; 339:1036-1042.
4. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756-1764.
5. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, et al.Bcl-2 expression as a predictive marker of hormone refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006; 12:6116-6124.
6. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19:2509-2516.
7. Petrylak D, Tangen C, Hussain M, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.
8. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chin KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
9. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, et al.Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23:3343-3351.
10. Oudard S, Banu E, Banu A, Scotte F, Levy E, Medioni J, et al. Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer patients: a meta-analysis of 3-year overall survival results. J Clin Oncol 2005; 23 (16S):4634.
11. Di Lorenzo G, Pizza C, Autorino R, De Laurentiis M, Marano O, D'Alessio A, et al. Weekly docetaxel and vinorelbine (VINDOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol 2004; 46: 712-716.
12. Kolodziej M, Neubauer M, Rousey SR, Pluenneke RE, Perrine G, Mull S, et al. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006; 5:155-161.
13. Marur S, Eliason J, Heilburn L, Smith D, Dickow B, Santucci R, et al. Phase II trial of oral capecitabine (C) and weekly docetaxel (D) in patients with metastatic androgen independent prostate cancer (AIPC). J Clin Oncol 2007; 25 (18S):5121.
14. Berry WR, Hathorn JW, Dakhil SR, Loesch DM, Jackson DV, Gregurich MA, et al.Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer 2004; 3:104-111.
15. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 11:1843-1849.
16. Milross CG, Mason KA, Hunter NR, Ching WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996; 88:1308-1314.
17. Vaishampayan U, Fontana J, Du W, Hussain M. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology 2002; 60:1050-1054.
18. Chiappino I, Destefanis P, Addeo A, Galetto A, Cucchiarale G, Munoz F, et al.Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer. Am J Clin Oncol 2007; 30:234-238.
19. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006; 4:CD005247.
20. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997; 79:196-202.
21. Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Valduga F, et al. A multicentric phase II randomized trial of docetaxel plus estramustine versus docetaxel as first line chemotherapy for patients with hormone-refractory advanced prostate cancer. J Clin Oncol 2006; 24 (18S):4625.
22. Eymard JC, Priou F, Zannetti A, Ravaud A, Lepille D, Kerbrat P, et al. Randomized phase II study of docetaxel plus estramustine and single agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007; 18:1064-1070.
23. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007; 8:994-1000.
24. Machiels JH, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, et al.Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol 2007; 25 (18S):5067.
25. Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK. Response to vinorelbine with or without estrmustine as second line chemotherapy in patients with hormone refractory prostate cancer. Cancer J 2007; 12:125-129.
26. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55:2325-2333.
27. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity: a comprehensive review of the biological basis of activity of epothilones as well as an overview of agents with an accompanying review of preclinical and clinical data. J Clin Oncol 2004; 22:2015-2025.
28. Hussain M, Tangen CM, Lara PN Jr, Vaishampayan UN, Petrylak DP, Colevas AS, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005; 23: 8724-8729.
29. Lin AM, Rosenberg JE, Weinberg VK, Kelly WK, Michaelson MD, Hussain M, et al.Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP). J Clin Oncol 2006; 24 (18S):4558.
30. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23:1439-1446.
31. Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003; 21:1866-1873.
32. Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23:2726-2734.
33. Tannock I. Cisplatinum and hormones in cancer of prostate. Urology 1980; 16:331-332.
34. Castagneto B, Ferraris V, Perachino M, Cafferata M, Giaretto L, Cavalli V, et al.Weekly administration of standardized low-disk carboplatin (CBDCA) in the treatment of advanced hormone-refractory prostate cancer (HRPC): a phase II study. Proceedings ASCO Prostate Cancer Symposium 2006, abs#243.
35. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, et al. A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003; 98:2592-2598.
36. Oh WK, George DJ, Tay MH. Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. Clin Prostate Cancer 2005; 4:61-64.
37. Sternberg CN, Petrylak D, Witjes F, Ferrero J, Eymard J, Falcon S, et al. Satraplatin (S) demonstrated significant clinical benefits for the treatment of patients with HRPC; results of a randomized phase III trial. J Clin Oncol 2007; 25 (18S):5019.
38. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165-176.
39. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000; 31:578-583.
40. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 39:246-261.
41. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001; 20:333-349.
42. Festuccia C, Teti A, Bianco P, Guerra F, Vicentini C, Tennina R, et al. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma. Oncol Res 1997; 9:419-431.
43. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003; 9:2587-2597.
44. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19:18-54.
45. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999; 6:333-347.
46. Murray RM, Grill V, Crinis N, Ho PW, Davison J, Pitt P. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 2001; 86:4133-4138.
47. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882.
48. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21: 3335-3342.
49. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21:4277-4284.
50. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002; 5:231-235.
51. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168:1005-1007.
52. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial). J Natl Cancer Inst 2003; 95:1300-1311.
53. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111:783-791.
54. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59-69.
55. Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000; 11 (Suppl 6):S18-S29.
56. Hegele A, Wahl HG, Varga Z, Sevinc S, Koliva L, Schrader AJ, et al.Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int 2007; 99:330-334.
57. Lein M, Wirth M, Miller K, Eickenberg HU, Weibach L, Schmidt K, et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007; 52:1381-1387.
58. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006; 12:3361-3367.
59. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997; 126:83-90.
60. Getzenberg RH, Light BW, Lapco PE, Konety BT, Nangia AK, Acierno JS, et al.Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997; 50:999-1006.
61. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001; 7:1043-1051.
62. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001; 28:49-55.
63. 3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 1999;5:695-703.
64. Ahmed S, Johnson CS, Rueger RM, Trump DL. Calcitriol (1,25- dihydroxycholecalciferol) potentiates activity of mitoxantrone/ dexamethasone in an androgen independent prostate cancer model. J Urol 2002; 168:756-761.
65. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high dose calcitriol and docetaxel in metastatic androgen independent prostate cancer. J Clin Oncol 2003; 21:123-128.
66. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT. J Clin Oncol 2007; 25:669-674.
67. Holt PR, Arber N, Halmos B, Forde K, Kissileff H, McGlynn KA, et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 2002; 11: 113-119.
68. Cantorna MT, Munsick C, Bermiss C, Mahon BD. 1,25 dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648-2652.
69. Kitano Y, Kurihara H, Kurihara Y, Maemura K, Ryo Y, Yazaki Y, et al.Gene expression of bone matrix proteins and endothelin receptors in endothelin-1-deficient mice revealed by insitu hybridization. J Bone Miner Res 1998; 13:237-244.
70. Levin ER. Endothelins. N Engl J Med 1995; 333:356-363.
71. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, et al.Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1:944-949.
72. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, et al.A casual role for endothelin-1 in the pathogenesis of osteoblastic bone metastasis. Proc Natl Acad Sci U S A 2003; 100:10954-10959.
73. Davar G, Hans G, Fareed MU, Sinnot C, Strichartz G. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 1998; 9:2279-2283.
74. Pflug BR, Zheng H, Udan MS, D'Antonio JM, Marshall FF, Brooks JD, et al.Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett 2007; 246:139-148.
75. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, et al.Pharmacological characterization of A-127722: an orally active and highly potent ETA selective receptor antagonist. J Pharmacol Exp Ther 1996; 276:473-481.
76. Carducci MA, Padley RJ, Bruel J, Vogelzang NJ, Zonnenberg BA, Daliani DD, et al.Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21:679-689.
77. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110:1959-1966.
78. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006; 107:530-535.
79. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, et al.In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007; 67: 3818-3826.
80. Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Lopez Beltran A, et al. Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol 2007; 52: 1682-1689.
81. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor- induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362:841-844.
82. Picus J, Halabi S, Rini B, Vogelzang N, Whang Y, Kaplan E, et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003; 22:(Abstr 1578).
83. Guerin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, et al.Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel: a new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008; 134:51-57.
84. L protein levels. Cell Death Differ 2000; 7:574-586.
85. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Writtke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997; 89:1027-1036.
86. Bauer JJ, Sesterhenn IA, Mostofi FK, Mcleod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regular proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156:1511-1516.
87. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, et al.A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11:3854-3861.
88. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al.Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8:3438-3444.
89. Sirotnak FM, She Y, Lee F, Chen J, Scher HI. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002; 8:3870-3876.
90. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, et al.Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005; 23:455-460.
91. Salzberg M, Rochlitz C, Morant R, Thalmann G, Pedrazzini A, Roggero E, et al. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie 2007; 30: 355-360.
92. De Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Felchon A, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-näive patients with hormone-refractory prostate cancer. J Clin Oncol 2007; 25:257-262.